Glenna Bett, PhD

Glenna Bett, PhD, co-founded Cytocybernetics, a spin-off firm of UB that is developing biotechnology to enhance drug safety screening. The new technology could halve the time and money needed to bring new drugs to the market.

Areas of Research

Our research spans from basic through translational and clinical, primarily focusing on determining the basic molecular bases of physiology and pathophysiology of women’s health and reproduction.

Topics include:

  • molecular basis of activity of the GnRH neuron, a major controller of fertility
  • excitation-contraction coupling in the uterus in normal and preterm labor
  • sex differences in electrical activity of the heart
  • effect of pregnancy on the heart
  • drug-induced arrhythmias
  • methods to improve FDA-mandated drug safety screening